Vixiar Medical, Inc., a Baltimore, Maryland-based company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, closed a $1.5m financing.
Backers included new investors Emerald Development Managers, MMG Opportunities and several individual investors and existing investors The Maryland Technology Development Corporation (TEDCO) through its seed fund, the Abell Foundation, individual investors and management.
The company intends to use the proceeds to complete an ongoing clinical trial and to prepare regulatory submissions.
Led by CEO Kevin Thibodeau, Vixiar develops non-invasive technologies for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The company’s first product, Indicor™, is a handheld point-of-care device and digital platform for the early detection and monitoring of worsening heart failure.
Vixiar is a spinout of Johns Hopkins.
FinSMEs
20/03/2019